Elan Injunction; Royalty Pharma Issues Grossly Misleading Statement; Elan to Pursue Royalty Pharma's Misrepresentations and Lack of Disclosure with Relevant Authorities; US District Court Issues Temporary Restraining Order

DUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE: ELN) (Elan) announces that earlier today Royalty Pharma issued a grossly misleading statement regarding the outcome yesterday of Elan's Irish High Court proceedings. On June 3, 2013, the Court prohibited Royalty Pharma from disseminating a Proxy Statement which, Elan believes, breached the Irish Takeover Rules. Yesterday, Royalty Pharma confirmed in Court in Dublin that it would not further disseminate its proxy statement until the Irish Takeover Panel determined whether it complied with Irish Takeover Rules. In the light of Royalty Pharma's assurances, Elan did not need to seek the continuance of its injunction.